Comorbidity, treatment and mortality: A population based cohort study of prostate cancer in PCBaSe Sweden

Journal of Urology

Volumn 185, Issue 3, 2011, Pages 833-840

  Berglund, Anders ^a,c   Garmo, Hans ^c,e   Tishelman, Carol ^a,b   Holmberg, Lars ^c,e   Stattin, Pr ^d   Lambe, Mats ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Stockholms Sjukhem Foundation   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

comorbidity; mortality; prostatic neoplasms; risk; therapeutics

Indexed keywords

GONADORELIN DERIVATIVE;

AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER THERAPY; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SWEDEN;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 79851509522     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.10.061     Document Type: Article

References (29)

1. R. Yancik Population aging and cancer: a cross-national concern Cancer J 11 2005 437
2. M. Wolbers, M.T. Koller, and J.C. Witteman Prognostic models with competing risks: methods and application to coronary risk prediction Epidemiology 20 2009 555
3. E. Hagel, H. Garmo, and A. Bill-Axelson PCBaSe Sweden: a register-based resource for prostate cancer research Scand J Urol Nephrol 43 2009 342
4. J. Adolfsson, H. Garmo, and E. Varenhorst Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 Scand J Urol Nephrol 41 2007 456
5. Ddsorsaker 2006 (Cause of Death): Epidemiologic Centre, National Board of Health and Welfare 2008
6. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373
7. M.S. Pepe, and M. Mori Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12 1993 737
8. R Development Core Team 2009. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
9. D. Scherr, P.W. Swindle, and P.T. Scardino National Comprehensive Cancer Network guidelines for the management of prostate cancer Urology 61 2003 14
10. J.E. Johansson, O. Andren, and S.O. Andersson Natural history of early, localized prostate cancer JAMA 291 2004 2713
11. P. Stattin, E. Holmberg, and J.E. Johansson Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study J Natl Cancer Inst 102 2010 950
12. G.W. Chodak, R.A. Thisted, and G.S. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242
13. H.I. Hall, W.A. Satariano, and T. Thompson Initial treatment for prostate carcinoma in relation to comorbidity and symptoms Cancer 95 2002 2308
14. L.C. Harlan, A. Potosky, and F.D. Gilliland Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcomes Study J Natl Cancer Inst 93 2001 1864
15. K.L. Schwartz, S.M. Alibhai, and G. Tomlinson Continued undertreatment of older men with localized prostate cancer Urology 62 2003 860
16. S. Houterman, M.L. Janssen-Heijnen, and A.J. Hendrikx Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study Crit Rev Oncol Hematol 58 2006 60
17. P.N. Post, P.J. Kil, and A.J. Hendrikx Comorbidity in patients with prostate cancer and its relevance to treatment choice BJU Int 84 1999 652
18. S. Houterman, M.L. Janssen-Heijnen, and C.D. Verheij Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study Prostate Cancer Prostatic Dis 9 2006 179
19. W.H. Hall, A.B. Jani, and J.K. Ryu The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer Prostate Cancer Prostatic Dis 8 2005 22
20. P.N. Post, B.E. Hansen, and P.J. Kil The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study BJU Int 87 2001 821
21. S.M. Alibhai, M. Leach, and G. Tomlinson 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity J Natl Cancer Inst 97 2005 1525
22. L. Lund, M. Borre, and J. Jacobsen Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study Urology 72 2008 1258
23. A. Tavani, S. Gallus, and M. Bertuzzi Diabetes mellitus and the risk of prostate cancer in Italy Eur Urol 47 2005 313
24. M. Froehner, R. Koch, and R.J. Litz Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy Eur Urol 47 2005 190
25. M. Van Hemelrijck, J. Adolfsson, and H. Garmo Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden Lancet Oncol 11 2010 450
26. M. Van Hemelrijck, H. Garmo, and L. Holmberg Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448
27. K. Fall, F. Stromberg, and J. Rosell Reliability of death certificates in prostate cancer patients Scand J Urol Nephrol 42 2008 352
28. C. Kastner, J. Armitage, and A. Kimble The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting Prostate Cancer Prostatic Dis 9 2006 270
29. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187